Arpeggio Bio

Active

Arpeggio Bio develops drugs targeting transcription factors using AI…

Summer 2019Founded 201820 peopleBoulder, CO, USA

↻ Pivot / rename signal

This company has previously operated under “Arpeggio Biosciences”. A rename frequently marks a pivot in positioning or product — useful raw material for variant ideas.

About

Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.